D-serine Added To Antipsychotics For The Treatment Of Schizophrenia
| 効果 | 増加 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 28 |
| 性別 | 男女 |
| 年齢 | 18-29, 30-44, 45-64 |
Supplementation of 30mg/kg D-serine to schizophrenic patients for 6 weeks was able to reduce all symptoms of schizophrenia, and serum concentrations of D-serine were able to predict the improvements seen in rating scales.
D-serine Efficacy As Add-on Pharmacotherapy To Risperidone And Olanzapine For Treatment-refractory Schizophrenia
| 効果 | 増加 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 39 |
| 性別 | 男女 |
| 年齢 | 30-44, 45-64 |
30mg/kg of D-serine daily in addition to antipsychotic therapy (risperidone or olanzapine) was able to improve negative, positive, depressive, and cognitive scores over 6 weeks with the improvement on symptoms being 4.3-20.6% (95% CI of SAS rating scale), 19.8-57.7% (95% CI of AIMS), and 14 patients on D-serine noted over a 20% improvement on negative and positive symptoms while only 2 subjects on placebo did.
A Multicenter, Add-on Randomized Controlled Trial Of Low-dose D-serine For Negative And Cognitive Symptoms Of Schizophrenia
| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 6+ ヶ月 |
| 被験者数 | 195 |
| 性別 | 男女 |
| 年齢 | 18-29, 30-44, 45-64 |
In 195 persons with schizophrenia already on antipsychotic treatment, the addition of 2,000mg D-serine daily for 16 weeks failed to outperform placebo at controlling positive and negative symptoms of schizophrenia and failed to significantly affect cognition.